Idioma:

Linezolid vs glycopeptides in the treatment of glycopeptide-susceptible Enterococcus faecium bacteraemia: A propensity score matched comparative study

Echeverria-Esnal, D. ; Sorli, L. ; Prim, N. ; Conde-Estévez, D. ; Mateu-De Antonio, J. ; Martin-Ontiyuelo, C. ; Horcajada, J.P. ; Grau, S.

International journal of antimicrobial agents, 2019-11, Vol.54 (5), p.572-578 [Periódico revisado por pares]

Netherlands: Elsevier B.V

Texto completo disponível

Citações Citado por

Enviar para

Título:
Linezolid vs glycopeptides in the treatment of glycopeptide-susceptible Enterococcus faecium bacteraemia: A propensity score matched comparative study
Autor: Echeverria-Esnal, D. ; Sorli, L. ; Prim, N. ; Conde-Estévez, D. ; Mateu-De Antonio, J. ; Martin-Ontiyuelo, C. ; Horcajada, J.P. ; Grau, S.
Assuntos: Adult ; Aged ; Anti-Bacterial Agents - therapeutic use ; Bacteremia - drug therapy ; Bacteremia - microbiology ; Bloodstream infection ; Enterococcus faecium ; Enterococcus faecium - drug effects ; Female ; Glycopeptides - therapeutic use ; Gram-Positive Bacterial Infections - drug therapy ; Gram-Positive Bacterial Infections - microbiology ; Humans ; Linezolid ; Linezolid - therapeutic use ; Male ; Middle Aged ; Propensity Score ; Retrospective Studies ; Teicoplanin - therapeutic use ; Treatment Outcome ; Vancomycin ; Vancomycin - therapeutic use
É parte de: International journal of antimicrobial agents, 2019-11, Vol.54 (5), p.572-578
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
Descrição: •The bacteraemia rate for Enterococcus faecium is increasing.•The treatment of choice remains unknown.•In this study, linezolid and glycopeptides showed similar clinical effectiveness.•Linezolid could be an alternative to glycopeptides. The incidence of ampicillin-resistant Enterococcus faecium bacteraemia is increasing. Vancomycin remains the first-line treatment in areas with a high prevalence of glycopeptide-susceptible isolates, but data comparing its clinical outcomes with other treatments are lacking. The objective of this study was to compare the effectiveness and safety of linezolid and glycopeptides for the treatment of glycopeptide-susceptible E. faecium bloodstream infection (GSEF-BSI). This retrospective observational cohort study was conducted from January 2006 to May 2018 at the Hospital del Mar, Barcelona, Spain, and compared the clinical outcomes and safety of linezolid and glycopeptides in adult patients with GSEF-BSI. The main outcomes included clinical cure at the end of therapy, 30-day mortality, microbiological eradication and attributable length of stay (LOS). Propensity score matching was performed to reduce potential confounders among groups. In total, 105 patients with GSEF-BSI were included (linezolid, n=38; glycopeptides, n=67). After propensity score matched analysis, 56 (53.3%) patients, 28 in each cohort, entered the final analysis. No differences were observed in any of the main clinical outcomes among patients treated with linezolid or glycopeptides: clinical cure [16/28 (57.1%) vs 13/28 (46.4%), P=0.593], 30-day mortality [8/28 (28.6%) vs 12/28 (42.9%), P=0.403], microbiological eradication [22/28 (78.6%) vs 20/28 (71.4%), P=0.758] and median attributable LOS (18.0 vs 17.0 days, P=0.924). Adverse events were similar in both groups. Linezolid and glycopeptides showed similar clinical effectiveness and safety in the treatment of GSEF-BSI. Linezolid could be an alternative to glycopeptides in the treatment of GSEF-BSI.
Editor: Netherlands: Elsevier B.V
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Linezolid vs glycopeptides in the treatment of glycopeptide-susceptible Enterococcus faecium bacteraemia: A propensity score matched comparative study

Echeverria-Esnal, D. ; Sorli, L. ; Prim, N. ; Conde-Estévez, D. ; Mateu-De Antonio, J. ; Martin-Ontiyuelo, C. ; Horcajada, J.P. ; Grau, S.

Netherlands: Elsevier B.V

Buscando em bases de dados remotas. Favor aguardar.